Akeso (SEHK:9926) Stock Looks Discounted Against Future Cash Flow Estimates

Akeso has seen its share price swing sharply over recent years, and investors now face a clear question about whether the current Hong Kong listing price is adequately supported by the company’s cash flows. With sentiment recently influenced by new lung cancer trial data, the focus has shifted to what the underlying numbers say about intrinsic value rather than just the headlines.

• Over the past 3 years, Akeso has delivered a share price gain of about 143.3%, which places extra weight on whether the underlying cash generation can sustain that kind of share price journey.
• Positive overall survival results for ivonescimab in PD-L1-positive advanced non small cell lung cancer may support expectations for future cash flows, if the therapy progresses through regulatory processes and commercial rollout as management intends.
• What if you looked at Akeso through its sales instead? See why Akeso's 20.6x P/S tells a different valuation story.

The stock’s next move may depend on whether Akeso’s current market price fairly reflects the intrinsic value suggested by its projected cash flows.

To see how Akeso compares with other opportunities built on discounted cash flow estimates rather than headlines, line it up next to 1 high quality undervalued stocks.

Does Akeso Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach for Akeso focuses on what its future cash generation could look like rather than where earnings sit today. Latest twelve month free cash flow is a loss of about CN¥1.46b, so the model leans heavily on expectations that cash flows recover and then grow over time as the pipeline matures.

Analyst projections used in the DCF point to Akeso moving from that cash burn into sizeable positive free cash flow in the early 2030s, with estimated figures reaching several billions of CN¥ per year. Because the DCF output sits substantially above the current HK$90.40 share price, the gap suggests investors today are paying a lower price than those long range cash flow assumptions imply. The strong overall survival data for ivonescimab against pembrolizumab helps explain why some holders may be comfortable with those optimistic long term cash flow paths, even if the near term financials still show pressure. Find out what Akeso could be worth using our Discounted Cash Flow (DCF) estimate.

The Akeso Narrative: What Would Justify Today's Price?

Akeso’s Simply Wall St Narratives pick up where the DCF puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, and they sit on the Community page. Rather than relying on a single multiple or model line, each narrative lays out the assumptions sitting behind its view of fair value so you can compare those with Akeso’s results as they arrive.

One of the top community narratives on Akeso: 43% undervalued

"Akeso's strategy to include their bispecific antibodies, cadonilimab and ivonescimab, in China's National Reimbursement Drug List aims to significantly expand market access..."

Discover why this Narrative puts Akeso at 43% undervalued.

Before acting on Akeso’s valuation, look at who is steering the ship

Price and cash flows tell only part of Akeso’s story, because the people setting priorities and how they are rewarded can tilt outcomes in very different directions. See who runs Akeso and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com